X

Trial Profile

Prospective, Randomized Trial of the Sirolimus-Eluting Stent and Paclitaxel-Eluting Stent for the Treatment of Unprotected Left Main Coronary Artery Disease(ISAR-LEFT-MAIN).

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 20 Oct 2022

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Sirolimus (Primary) ; Paclitaxel
Indications Coronary artery disease; Coronary artery restenosis; Myocardial ischaemia
Focus Pharmacodynamics; Therapeutic Use
Acronyms ISAR-LEFT-MAIN

Most Recent Events

28 Aug 2010 Data pertaining to the impact on left ventricular function presented at the Annual Congress of the European Society of Cardiology (ESC) 2010.
12 May 2009 Results reported in the Journal of the American College of Cardiology.
20 Oct 2008 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com